Kinnari Patel - 21 Nov 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
President, Head of R&D and Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
Issuer symbol
RCKT
Transactions as of
21 Nov 2024
Net transactions value
-$59,892
Form type
4
Filing time
25 Nov 2024, 16:05:18 UTC
Previous filing
20 Aug 2024
Next filing
13 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Sale $59,892 -4,588 -1.2% $13.05 392,395 21 Nov 2024 Direct F1, F2
holding RCKT Common Stock 5,675 21 Nov 2024 By Spouse
holding RCKT Common Stock 104,927 21 Nov 2024 By Adaptive Technology LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
F3 The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.

Remarks:

President, Head of R&D and Chief Operating Officer